NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd
Post# of 122
(Total Views: 167)
Posted On: 03/06/2023 3:09:08 PM
NetworkNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is spotlighted in a recent episode of the “Test. Optimize. Scale.” podcast series, which features industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. BiondVax CEO Amir Reichman is a guest of the popular on-demand podcast, which is hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency. During the podcast, Reichman talked about his journey leading up to joining BiondVax in 2021 as well as the company’s current plans, which include developing a derisked pipeline of diversified and commercially viable products and platforms, including an innovative nanosized antibody (“NanoAb”) pipeline licensed from the Max Planck Society. “[BiondVax] had a company with a super team that knew how to develop drugs from zero to 100 and manage budget,” said BiondVax CEO Amir Reichman during the podcast. “They had massive labs and facilities. . . . However, they had $2.5 million in the bank and the IP [for its universal influenza vaccine] had basically flopped [in a phase 3 trial]. . . .It was an excellent opportunity. . . to in-license a new technology to the company. It becomes a new company in a very early stage, but with a massive edge over others. The team is super experienced in running trials. . . the capacity and capabilities are there. If we raise enough money with a nice business plan, we can in-license a technology and have a good start.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is spotlighted in a recent episode of the “Test. Optimize. Scale.” podcast series, which features industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. BiondVax CEO Amir Reichman is a guest of the popular on-demand podcast, which is hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency. During the podcast, Reichman talked about his journey leading up to joining BiondVax in 2021 as well as the company’s current plans, which include developing a derisked pipeline of diversified and commercially viable products and platforms, including an innovative nanosized antibody (“NanoAb”) pipeline licensed from the Max Planck Society. “[BiondVax] had a company with a super team that knew how to develop drugs from zero to 100 and manage budget,” said BiondVax CEO Amir Reichman during the podcast. “They had massive labs and facilities. . . . However, they had $2.5 million in the bank and the IP [for its universal influenza vaccine] had basically flopped [in a phase 3 trial]. . . .It was an excellent opportunity. . . to in-license a new technology to the company. It becomes a new company in a very early stage, but with a massive edge over others. The team is super experienced in running trials. . . the capacity and capabilities are there. If we raise enough money with a nice business plan, we can in-license a technology and have a good start.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)